Global Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Globoid Cell Leukodystrophy (Krabbe Disease) treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Advanced Pharmaceuticals LLC, Commence Bio Inc, GlaxoSmithKline, Kyorin Pharmaceutical Co Ltd, Magenta Therapeutics Inc and others.
A Significant contribution to the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Globoid Cell Leukodystrophy (Krabbe Disease) pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Globoid Cell Leukodystrophy (Krabbe Disease) condition and increased access to investments is encouraging growth of Globoid Cell Leukodystrophy (Krabbe Disease) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Globoid Cell Leukodystrophy (Krabbe Disease) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Globoid Cell Leukodystrophy (Krabbe Disease) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Globoid Cell Leukodystrophy (Krabbe Disease) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Globoid Cell Leukodystrophy (Krabbe Disease). Further, orphan drug status, fast track designation, grants awarded and other special status for Globoid Cell Leukodystrophy (Krabbe Disease) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Globoid Cell Leukodystrophy (Krabbe Disease) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline candidates-
A Significant contribution to the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Globoid Cell Leukodystrophy (Krabbe Disease) pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Globoid Cell Leukodystrophy (Krabbe Disease) condition and increased access to investments is encouraging growth of Globoid Cell Leukodystrophy (Krabbe Disease) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Globoid Cell Leukodystrophy (Krabbe Disease) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Globoid Cell Leukodystrophy (Krabbe Disease) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Globoid Cell Leukodystrophy (Krabbe Disease) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Globoid Cell Leukodystrophy (Krabbe Disease). Further, orphan drug status, fast track designation, grants awarded and other special status for Globoid Cell Leukodystrophy (Krabbe Disease) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Globoid Cell Leukodystrophy (Krabbe Disease) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Globoid Cell Leukodystrophy (Krabbe Disease) drugs
- Late phase: Phase 3 and in-approval Globoid Cell Leukodystrophy (Krabbe Disease) drugs
- Company overview
- Snapshot
- Globoid Cell Leukodystrophy (Krabbe Disease) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Disease Overview
2.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Snapshot
2.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Drugs by Phase
2.4 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Drugs by Company
2.5 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Advanced Pharmaceuticals LLC Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.2 Commence Bio Inc Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.3 GlaxoSmithKline Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.4 Kyorin Pharmaceutical Co Ltd Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.5 Magenta Therapeutics Inc Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.6 Ranedis Pharmaceuticals LLC Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 1 Drug Details
4.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 1 Drug Overview
4.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 2 Drug Details
5.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 2 Drug Overview
5.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 3 Drug Details
6.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 3 Drug Overview
6.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Pre-clinical Phase Drug Details
7.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Pre-clinical Phase Drug Overview
7.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Disease Overview
2.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Snapshot
2.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Drugs by Phase
2.4 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Drugs by Company
2.5 Globoid Cell Leukodystrophy (Krabbe Disease)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Advanced Pharmaceuticals LLC Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.2 Commence Bio Inc Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.3 GlaxoSmithKline Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.4 Kyorin Pharmaceutical Co Ltd Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.5 Magenta Therapeutics Inc Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
3.6 Ranedis Pharmaceuticals LLC Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 1 Drug Details
4.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 1 Drug Overview
4.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 2 Drug Details
5.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 2 Drug Overview
5.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 3 Drug Details
6.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 3 Drug Overview
6.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Globoid Cell Leukodystrophy (Krabbe Disease)- Pre-clinical Phase Drug Details
7.2 Globoid Cell Leukodystrophy (Krabbe Disease)- Pre-clinical Phase Drug Overview
7.3 Globoid Cell Leukodystrophy (Krabbe Disease)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
